ArticleCureus2025
Thyroxine Reveals Addison's Disease: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Case Report: Primary aldosteronism coexisting with adrenal insufficiency in a 73-year-old woman with paradoxical hyponatremia.Frontiers in immunology · 2026Article
- The "polyglandular crisis" behind recurrent hyponatremia: misdiagnosis of a case of autoimmune polyglandular syndrome type 2 and clinical lessons learned.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune polyglandular syndrome type 2 (APS-2) is a rare complex autoimmune endocrinological entity and is reported even more rarely in children and adolescents. It consists of primary adrenal insufficiency (Addison's disease), autoimmune thyroiditis (AIT) and/or type 1 diabetes mellitus (T1DM). Treatment of the AIT component of the disease with levothyroxine as hormone replacement therapy has been reported rarely to cause adrenal crisis. This treatment adverse event is possibly explained due to the increase of basal metabolic rate and subsequently the increased demand and clearance of cortisol after levothyroxine therapy and should always be considered by physicians in order to avoid the development of adrenal crisis. We report the case of a 13-year-old adolescent girl with hypothyroidism due to Hashimoto's thyroiditis (HT) who developed signs of adrenal insufficiency after initial levothyroxine therapy. She was initially admitted with symptoms of hyperthyroidism, including weight loss, anxiety, and oligomenorrhea. A more thorough examination revealed pallor, signs of dehydration, tachycardia, and additionally serum electrolyte imbalance and extremely low cortisol levels in combination with very high adrenocorticotropic hormone (ACTH) levels. The patient received emergency treatment for adrenal insufficiency and recovered well. Due to positive adrenal autoantibodies, APS-2 was confirmed. This case report highlights the necessity of careful adrenal function screening in patients with hypothyroidism and HT before initiating thyroid therapy in order to avoid the rare occurrence of adrenal crisis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.